A Wellesley company called NormOxys has tossed aside its cloak of secrecy and is talking publicly about its technology. According to the company’s website, NormOxys “is developing a technology platform for an exciting new class of small molecule drugs called oxyrens: oxygen release enhancers. Oxyrens enhance the body’s ability to deliver oxygen more efficiently to all tissues that need it and offer breakthrough treatments for a wide variety of disorders, including cancer, cardiovascular diseases, anemia, Alzheimer’s disease, stroke and diabetic retinopathy.”
The company, which has raised more than $12 million in venture funding, has a strong pedigree, with one of its cofounders a Nobel laureate.
More on the company here from Xconomy.